Arbor Biotechnologies company information, Employees & Contact Information

Arbor Bio in $2B+ deal with Chiesi for gene editing therapies BioWorld MedTech

Arbor Biotechnologies Announces $73.9 Million Series C Financing to Advance Novel Gene Editing Therapeutics GlobeNewswire

Chiesi fertilizes Arbor's rare disease gene therapy efforts with $2B biobucks deal Fierce Biotech

Chiesi buys into Arbor gene editing drug for rare kidney disease BioPharma Dive

Arbor Raises $73.5M To Ride Out Gene Editing’s ‘Gartner Hype Cycle’ BioSpace

From Tools to Trials: Editing Therapy Companies Pivot to Development Genetic Engineering and Biotechnology News

Trial launches of ABO-101 for primary hyperoxaluria type 1 Urology Times

Chiesi Group and Arbor Biotechnologies Announce a Global GlobeNewswire

Clinical trial: Primary Hyperoxaluria Type 1, (NCT06839235) CRISPR Medicine News

Chiesi, Arbor Weave $2.1B Rare Disease Pact BioSpace

Arbor raises $74M amid genetic medicine’s funding slump BioPharma Dive

Arbor sails into rocky gene editing waters with $74M for rare liver disease therapy Fierce Biotech

Arbor Biotechnologies Announces First Patient Dosed at Mayo Clinic in the redePHine Phase 1/2 Study of ABO-101, an Investigational Gene Editing Treatment for Primary Hyperoxaluria Type 1 GlobeNewswire

FDA greenlights phase 1/2 trial of gene editing therapy for primary hyperoxaluria 1 Urology Times

A radiopharmaceuticals startup raises $175 million statnews.com

FDA awards orphan drug, rare pediatric disease designations to ABO-101 for PH1 Urology Times

Arbor Biotechnologies Appoints Don Haut, Ph.D., as Chief Business Officer GlobeNewswire

Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers Fierce Biotech

Arbor Biotechnologies Announces FDA Orphan Drug and Rare Pediatric Disease Designations Granted to ABO-101 for the Treatment of Primary Hyperoxaluria Type 1 (PH1) and Upcoming Presentations at the 20th Congress of the International Pediatric Nep GlobeNewswire

Arbor Biotechnologies Closes $215 Million Oversubscribed GlobeNewswire

Arbor's autumn: A $1.2B Vertex pact, now a $215M series B for liver, CNS diseases Fierce Biotech

John Murphy, PhD; and Tia DiTommaso, PhD, on Preclinical Evidence for PH1 Gene Therapy CGTLive®

Vertex layers on bluebird bio pressure with $1.2B Arbor gene-editing pact Fierce Biotech

Allogene, Arbor Team to Develop Off-the-Shelf CAR-T Therapies with CRISPR BioSpace

Arbor Biotechnologies Announces Expanded Strategic GlobeNewswire

Arbor Biotechnologies Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors Yahoo Finance

RBL LLC welcomes Devyn Smith to board of directors Rice University

Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease Yahoo Finance

Arbor Biotechnologies Appoints Dr. Daniel Ory as Chief Medical Officer citybiz

Vertex and Arbor Biotechnologies Establish New Partnership to Develop Novel ex vivo Engineered Cell Therapies GlobeNewswire

Editas Medicine at Chardan’s Conference: Gene Editing Insights Investing.com

Actio Biosciences Appoints Cayce Denton as Chief Financial Officer citybiz

Allogene taps Arbor in pursuit of ‘off-the-shelf’ CAR-T therapies for autoimmune disease BioPharma Dive

Arbor Biotechnologies Names Devyn Smith, Ph.D., as CEO GlobeNewswire

EdiGene and Arbor Biotechnologies Announce Worldwide GlobeNewswire

4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases Yahoo Finance

TCR² Therapeutics and Arbor Biotechnologies Establish Collaboration to Advance Allogeneic TRuC-T Cell Therapies GlobeNewswire

Ann Arbor-based Life Science Companies TSRL, AnchorBio, and AAPharmaSyn Launch The A2 BioPharm Collaborative at BIO 2025 BioSpace

Arbor’s ABO-101 awarded US orphan drug designation for primary hyperoxaluria type 1 BioWorld MedTech

Eco-friendly bioactives from Nyctanthes arbor-tristis (L.) for targeted control of Aedes aegypti and Culex quinquefasciatus with reduced impact on Toxorhynchites splendens Nature

U.S. says it has arrested another Chinese researcher accused of smuggling biological material NBC News

Mining (and Refining) the Stuff of Gene Editing Tools Genetic Engineering and Biotechnology News

2 Chinese nationals accused of smuggling "dangerous biological pathogen" into Michigan CBS News

Federal authorities make third arrest over smuggled biological materials to University of Michigan lab ClickOnDetroit | WDIV Local 4

Functionally diverse type V CRISPR-Cas systems Science | AAAS

Windfall Bio is seeing strong demand for its methane-eating microbe startup TechCrunch

Vertex and Arbor Strike a $1.2 Billion Deal for Gene-Editing Programs BioSpace

Arbor Rapha Capital Bioholdings Corp. I Announces Pricing of $150 Million Initial Public Offering BioSpace

Arbor Biosciences and LGC, Biosearch Technologies Partner on Marker Discovery and Genotyping in Agrigenomics BioSpace

UPDATED: Vertex signs another Mammoth-sized CRISPR deal with $650M in biobucks on the line Fierce Biotech

This is Epic: Epigenomic CRISPR Startup Goes Big by Thinking Small Genetic Engineering and Biotechnology News

Meet Debbie U.S. Representative Debbie Dingell (.gov)

Indianapolis program killed by federal government sought diversity ... among trees IndyStar

Curcumin Successfully Inhibited the Computationally Identified CYP2A6 Enzyme-Mediated Bioactivation of Aflatoxin B1 in Arbor Acres broiler Frontiers

With fresh support from its billionaire backers Pivot Bio is ushering in a farming revolution TechCrunch

Tim Roseberry MaxPreps.com

Biography University of Michigan

Arbor Pharmaceuticals, LLC Confirms Availability of Triptodur® (triptorelin) for Patients with Central Precocious Puberty BioSpace

Arbor Pharma buys XenoPort for $467 million BioPharma Dive

Meet Leelanau’s Own Music Man: Patrick Niemisto Glen Arbor Sun

Coloring efficacy of Nyctanthes Arbortristis based yellow natural dye for surface-modified wool ScienceDirect.com